Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEOs In Transition: Internal The Norm, But External Delivers Strong Returns

Executive Summary

CEO changes are underway across big pharma and biotech, marking a time of substantial leadership transition for the industry. New CEOs are usually insiders, but external hires appear to be more willing to implement change to improve shareholder returns, according to an analysis from Leerink.

Advertisement

Related Content

Novo Nordisk Names Jørgensen CEO As Sørensen Steps Down Early
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Scangos Leaves Biogen Transformed And Transitioning
CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel